Division of Bausch Health Companies Inc.
Latest From Santarus Inc.
Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.
Pharming Group, a company that has been on the drug development scene since the ‘80s, has recorded a quarterly net profit for the first time – two years earlier than previously forecast.
The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.
As major companies start to release their quarterly results over the next few weeks, Scrip and sister publication PharmAsia News take a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia's major corporate players.
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Senior Management
Gerald T Proehl, Pres. & CEO
Debra P Crawford, SVP, CFO
Blake A Boland, VP, Sales
Michael D Step, SVP, Corp. Dev.
Thomas J Joyce, VP, Mktg.
Wendell Wierenga, PhD, EVP, R&D
- Contact Info
Phone: (858) 314-5700
3721 Valley Centre Dr.
San Diego, CA 92130
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.